Renegotiation of Debt Facilit

RNS Number : 2088P

Allergy Therapeutics PLC

20 March 2009

 



Replacing RNS No: 2069P - wording amended

Friday 20 March 2009

Allergy Therapeutics plc

("Allergy Therapeutics" or "the Company")

Renegotiation of Debt Facilities

Allergy Therapeutics (AGY), the specialist pharmaceutical company focused on allergy vaccination, announces that it is in discussions with its bankers with the aim of renegotiating its debt facilities. The discussions are progressing well and the company is confident that they will be resolved swiftly. The company will make a further announcement in due course.

For further information

Allergy Therapeutics	[phone]
Keith Carter, Chief Executive
Ian Postlethwaite, Finance Director
www.allergytherapeutics.com
Nomura Code Securities	[phone]
Juliet Thompson
Financial Dynamics	[phone]
David Yates
Ben Brewerton

About Allergy Therapeutics

Allergy Therapeutics plc is a London Stock Exchange (AIM) listed, integrated specialist pharmaceutical company focused on allergy vaccination. It has a growing, profitable core business achieving sales of allergy vaccines of £31 million in Germany, Italy, Spain and other EU markets through its own sales and marketing infrastructure. The Company is expanding its infrastructure with operations also in the United Kingdom, Poland, the Czech Republic, Slovakia and Austria.

 

END

 

 

MSCBBGDXCGDGGCG